Pierre Gholam, MD

Pierre Gholam, MD, associate professor of medicine at Case Western Reserve University School of Medicine, discusses his approach to recognizing and managing adverse events in patients receiving tyrosine kinase inhibitors for hepatocellular carcinoma.

Pierre Gholam, MD, observes the improvements in outcomes with lenvatinib seen in recent trials of unresectable hepatocellular carcinoma compared with the original phase 3 REFLECT trial.

Pierre Gholam, MD, examines the limited trial data on treatment for patients with hepatocellular carcinoma (HCC) with worse Child-Pugh scores.

Pierre Gholam, MD, discusses the phase 3 RATIONALE-301 study of frontline tislelizumab vs sorafenib for patients with hepatocellular carcinoma.

Pierre Gholam, MD, discusses his thoughts on a phase 3 trial which evaluated camrelizumab plus rivoceranib vs sorafenib in the first-line for patients with unresectable hepatocellular carcinoma.

Pierre Gholam, MD, discusses the phase 3 LEAP-002 study of lenvatinib and pembrolizumab for unresectable hepatocellular carcinoma.

Pierre Gholam, MD, discusses standard of care options for hepatocellular carcinoma, including newly-available therapies.

A key opinion leader shares clinical practice pearls for the treatment of patients with unresectable HCC. 

Pierre Gholam, MD, discusses future directions and novel therapeutic agents for the treatment of unresectable HCC.

Gastroenterology expert, Dr Pierre Gholam, discusses the efficacy and safety data from the phase 3 IMbrave150 trial.

Dr Gholam reviews the study design and key data from the phase 3 REFLECT trial.

An expert in the treatment of HCC comments on first-line therapeutic options for patients with previously untreated, advanced HCC.

Dr Gholam, MD, provides expert analysis on the prognosis and treatment of a patient with unresectable HCC.

Pierre Gholam, MD, presents the case of a 61-year-old woman with hepatocellular carcinoma (HCC).

Pierre Gholam, MD, provides insight on the case of a 61-year-old man with stage 4 hepatocellular carcinoma and evaluates current treatment options on TKIs.